US FDA On Resuming Normal Manufacturing Operations When Pandemic Recedes
Focus on restarting production, easing drug shortages and completing quality assurance activities for quarantined batches, agency guidance says.
You may also be interested in...
How pharmaceutical companies should plan to catch up after the pandemic and explain what happened to inspectors.
The US Food and Drug Administration has issued final guidance aimed at encouraging manufacturers of so-called "medically necessary drug products" and their raw materials and components to develop contingency production plans for use during emergencies that result in high absenteeism at production facilities.
The US FDA shaved months from review of Gilead’s Veklury (remdesivir) for COVID-19 with post-approval commitments for multiple stability studies. The Pink Sheet takes a deep dive look at discussions within the agency and with the sponsor.